3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Hemangiosarcoma
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Disease Progression
1
Colonic Neoplasms
1
Carcinoma, Lobular
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Carboplatin
4
pertuzumab
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Paclitaxel
2
Oxaliplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
talazoparib
1
sarilumab
1
relugolix
1
regorafenib
1
pexidartinib
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
nimotuzumab
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Complete Response
×
neratinib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled